GLP-1semaglutideglp-1schizophreniaadverse-events

Schizophrenia Research meta-analysis weighs GLP-1 gastrointestinal risk in antipsychotic-treated patients

The authors also examine how tolerability is described in trials of GLP-1 receptor agonists given alongside antipsychotics.

By Maren Holt · Senior Reporter, GLP-1

Oct 17 20:00 ETSource: Schizophrenia research

The wire

01A meta-analysis in Schizophrenia Research assesses gastrointestinal risk and tolerability language across trials of GLP-1 receptor agonists in antipsychotic-treated schizophrenia.
02Prescribers managing antipsychotic-associated weight gain increasingly add incretin drugs, and GI adverse events are the most common reason patients stop them.
03Only the title and citation are posted so far; effect sizes, number of trials and pooled event rates need checking against the full paper.

From the source

Tolerability language and gastrointestinal risk in a meta-analysis of GLP-1 receptor agonists in antipsychotic-treated schizophrenia
Schizophrenia research · 2026 Oct 18 · Cotrik E, Da Silva AG et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42893627/